American Heart Journal
Volume 151, Issue 5 , Pages 1012.e1-1012.e5 , May 2006

Low prevalence of B-type natriuretic peptide levels <100 pg/mL in patients with heart failure at hospital discharge

  • Jochem Hogenhuis, MSc

      Affiliations

    • Corresponding Author InformationReprint requests. Jochem Hogenhuis, MSc Department of Cardiology, Thoraxcenter, University Medical Center Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands.
    • Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands
    • ,
  • Adriaan A. Voors, MD, PhD

      Affiliations

    • Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands
    • ,
  • Tiny Jaarsma, RN, PhD

      Affiliations

    • Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands
    • ,
  • Hans L. Hillege, MD, PhD

      Affiliations

    • Trial Coordination Center, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    • ,
  • Arno W. Hoes, MD, PhD

      Affiliations

    • Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
    • ,
  • Dirk J. van Veldhuisen, MD, PhD

      Affiliations

    • Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands

Received 26 August 2005 ,Accepted 24 December 2005.

References 

  1. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J. 2005;26:1115–1140
  2. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161–167
  3. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997;96:509–516
  4. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126–1130
  5. Caldwell MA, Howie JN, Dracup K. BNP as discharge criteria for heart failure. J Card Fail. 2003;9:416–422
  6. Tang WH, Girod JP, Lee MJ, et al. Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation. 2003;108:2964–2966
  7. Jaarsma T, van der Wal MHL, Hogenhuis J, et al. Design and methodology of the COACH study: a multicenter randomised Coordinating study evaluating Outcomes of Advising and Counselling in Heart failure. Eur J Heart Fail. 2004;6:227–233
  8. Tjeerdsma G, de Boer RA, Boomsma F, et al. Rapid bedside measurement of brain natriuretic peptide in patients with chronic heart failure. Int J Cardiol. 2002;86:143–149
  9. Wieczorek SJ, Wu AH, Christenson R, et al. A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. Am Heart J. 2002;144:834–839
  10. National Kidney Foundation . K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S46–S75
  11. Morrison LK, Harrision A, Krishnaswamy P, et al. Utility of a rapid B-type natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol. 2002;39:202–209
  12. Doust JA, Glasziou PP, Pietrzak E, et al. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med. 2004;164:1978–1984
  13. Mukoyama M, Nakao K, Saito Y, et al. Increased human brain natriuretic peptide in congestive heart failure. N Engl J Med. 1990;323:757–758
  14. Kazanegra R, Cheng V, Garcia A, et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail. 2001;7:21–29
  15. McCullough PA, Sandberg KR. Sorting out the evidence on natriuretic peptides. Rev Cardiovasc Med. 2003;4(Suppl 4):S13–S19
  16. Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004;109:594–600
  17. Krauser DG, Lloyd-Jones DM, Chae CU, et al. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. Am Heart J. 2005;149:744–750
  18. Sarzani R, Dessi-Fulgheri P, Paci VM, et al. Expression of natriuretic peptide receptors in human adipose and other tissues. J Endocrinol Invest. 1996;19:581–585
  19. Morabito D, Valloton MB, Lang U. Obesity is associated with impaired ventricular protein kinase C–MAP kinase signaling and altered ANP mRNA expression in the heart of adult Zucker rats. J Investig Med. 2001;49:310–318
  20. Licata G, Volpe M, Scaglione R, et al. Salt-regulating hormones in young normotensive obese subjects. Effect of saline load. Hypertension. 1994;23(Suppl):I20–I24
  21. Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol. 2004;43:635–641

 The NHF-COACH study is financially supported by the Netherlands Heart Foundation (Grant 2000Z003). Prof van Veldhuisen is an established investigator of the Netherlands Heart Foundation (Grant D97.017).

PII: S0002-8703(06)00007-X

doi: 10.1016/j.ahj.2005.12.012

American Heart Journal
Volume 151, Issue 5 , Pages 1012.e1-1012.e5 , May 2006

Article Tools

* Image Usage & Resolution